This is being developed in Israel, so it may be slightly beyond reach of Big Pharma. I dont know, at least it is out of reach of WHO, CDC, and other DS entities driving the vacvine solution. The reports are really promising for CV patients with more severe respiratory issues. HCQ+ works great if treatment is before respiratory failure, this may be the cure after HCQ+ becomes less effective on patients with respiratory failure. If it is all true, a wonderful development.